BG64018B1 - Фармацевтичен състав и неговото използване за регулиране на липидната концентрация - Google Patents

Фармацевтичен състав и неговото използване за регулиране на липидната концентрация Download PDF

Info

Publication number: BG64018B1
Authority: BG; Bulgaria
Prior art keywords: phenyl; methylethyl; pharmaceutical composition; composition according; bis
Prior art date: 1995-11-02

Application number

BG102417A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG102417A (en

Inventor

Thomas BOCAN

Original Assignee

Warner-Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-02

Filing date

1998-04-29

Publication date

2003-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21719566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64018(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-29 Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc

1999-01-29 Publication of BG102417A publication Critical patent/BG102417A/xx

2003-10-31 Publication of BG64018B1 publication Critical patent/BG64018B1/bg

Links

150000002632 lipids Chemical class 0.000 title claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 title claims description 31
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 34
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 29
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims abstract description 24
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims abstract description 24
229960005370 atorvastatin Drugs 0.000 claims abstract description 24
-1 atorvastatin Chemical class 0.000 claims abstract description 23
239000003112 inhibitor Substances 0.000 claims abstract description 15
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 13
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 11
235000012000 cholesterol Nutrition 0.000 claims abstract description 11
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 11
230000002792 vascular Effects 0.000 claims abstract description 7
230000003511 endothelial effect Effects 0.000 claims abstract description 6
230000000302 ischemic effect Effects 0.000 claims abstract description 6
230000001419 dependent effect Effects 0.000 claims abstract description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 32
150000001875 compounds Chemical class 0.000 claims description 21
230000006378 damage Effects 0.000 claims description 12
230000003143 atherosclerotic effect Effects 0.000 claims description 11
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 10
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 9
239000007983 Tris buffer Substances 0.000 claims description 9
229960002855 simvastatin Drugs 0.000 claims description 9
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims description 9
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 8
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 8
208000029078 coronary artery disease Diseases 0.000 claims description 7
229960004844 lovastatin Drugs 0.000 claims description 7
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 7
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 7
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 6
210000004204 blood vessel Anatomy 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
229960003765 fluvastatin Drugs 0.000 claims description 6
229960002965 pravastatin Drugs 0.000 claims description 6
230000015271 coagulation Effects 0.000 claims description 5
238000005345 coagulation Methods 0.000 claims description 5
230000024883 vasodilation Effects 0.000 claims description 5
WAFNZAURAWBNDZ-UHFFFAOYSA-N 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide Chemical compound CCCCCCCCCCC(C)(C)C(=O)NC1=C(OC)C=C(OC)C=C1OC WAFNZAURAWBNDZ-UHFFFAOYSA-N 0.000 claims description 4
PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 4
208000019693 Lung disease Diseases 0.000 claims description 4
VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 claims description 4
GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 4
NPQWVLZCVMVSEX-UHFFFAOYSA-N n-[2,6-di(propan-2-yl)phenyl]-2-(2-dodecyltetrazol-5-yl)-2-phenylacetamide Chemical compound CCCCCCCCCCCCN1N=NC(C(C(=O)NC=2C(=CC=CC=2C(C)C)C(C)C)C=2C=CC=CC=2)=N1 NPQWVLZCVMVSEX-UHFFFAOYSA-N 0.000 claims description 4
230000001105 regulatory effect Effects 0.000 claims description 4
206010002383 Angina Pectoris Diseases 0.000 claims description 3
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 3
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 3
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 3
206010021143 Hypoxia Diseases 0.000 claims description 3
230000001070 adhesive effect Effects 0.000 claims description 3
230000004075 alteration Effects 0.000 claims description 3
208000020832 chronic kidney disease Diseases 0.000 claims description 3
230000001146 hypoxic effect Effects 0.000 claims description 3
208000002815 pulmonary hypertension Diseases 0.000 claims description 3
206010038464 renal hypertension Diseases 0.000 claims description 3
KFDFYCRDUBAKHD-UHFFFAOYSA-M sodium;carbamate Chemical compound [Na+].NC([O-])=O KFDFYCRDUBAKHD-UHFFFAOYSA-M 0.000 claims description 3
ZLAJEWCTXKXIPN-UHFFFAOYSA-N 3-dodecoxy-3-oxopropanoic acid Chemical compound CCCCCCCCCCCCOC(=O)CC(O)=O ZLAJEWCTXKXIPN-UHFFFAOYSA-N 0.000 claims description 2
239000004952 Polyamide Substances 0.000 claims description 2
208000032109 Transient ischaemic attack Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
229920002647 polyamide Polymers 0.000 claims description 2
208000007056 sickle cell anemia Diseases 0.000 claims description 2
201000010875 transient cerebral ischemia Diseases 0.000 claims description 2
230000002265 prevention Effects 0.000 claims 5
FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 3
241000124008 Mammalia Species 0.000 claims 3
206010048554 Endothelial dysfunction Diseases 0.000 claims 2
206010042434 Sudden death Diseases 0.000 claims 2
230000008694 endothelial dysfunction Effects 0.000 claims 2
208000028867 ischemia Diseases 0.000 claims 2
230000000087 stabilizing effect Effects 0.000 claims 2
208000007502 anemia Diseases 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
230000001052 transient effect Effects 0.000 claims 1
102000004895 Lipoproteins Human genes 0.000 abstract description 10
108090001030 Lipoproteins Proteins 0.000 abstract description 10
230000001965 increasing effect Effects 0.000 abstract description 8
238000008214 LDL Cholesterol Methods 0.000 abstract description 7
208000011580 syndromic disease Diseases 0.000 abstract description 4
230000009467 reduction Effects 0.000 abstract description 3
229940122601 Esterase inhibitor Drugs 0.000 abstract 1
239000002329 esterase inhibitor Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 abstract 1
150000001840 cholesterol esters Chemical class 0.000 description 11
230000003902 lesion Effects 0.000 description 9
201000001320 Atherosclerosis Diseases 0.000 description 6
108010028554 LDL Cholesterol Proteins 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
210000002376 aorta thoracic Anatomy 0.000 description 5
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 5
239000000843 powder Substances 0.000 description 5
101710095342 Apolipoprotein B Proteins 0.000 description 4
102100040202 Apolipoprotein B-100 Human genes 0.000 description 4
108010023302 HDL Cholesterol Proteins 0.000 description 4
208000035150 Hypercholesterolemia Diseases 0.000 description 4
108010069201 VLDL Cholesterol Proteins 0.000 description 4
235000019864 coconut oil Nutrition 0.000 description 4
239000003240 coconut oil Substances 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
230000037213 diet Effects 0.000 description 4
210000001105 femoral artery Anatomy 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000003176 fibrotic effect Effects 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000003845 vascular endothelial function Effects 0.000 description 3
208000017667 Chronic Disease Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
102100030817 Liver carboxylesterase 1 Human genes 0.000 description 2
101710181187 Liver carboxylesterase 1 Proteins 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000000923 atherogenic effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
230000006872 improvement Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000010606 normalization Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
230000006442 vascular tone Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
VKOFYUWOHUCUBR-UHFFFAOYSA-N 2-[2,6-di(propan-2-yl)phenyl]-2-(2-dodecyltetrazol-5-yl)-2-phenylacetamide Chemical compound CC(C)C1=C(C(=CC=C1)C(C)C)C(C(=O)N)(C1=CC=CC=C1)C=1N=NN(N=1)CCCCCCCCCCCC VKOFYUWOHUCUBR-UHFFFAOYSA-N 0.000 description 1
HSHOXDTWEUKPND-UHFFFAOYSA-N 5-methoxy-5-oxopentaneperoxoic acid Chemical compound COC(=O)CCCC(=O)OO HSHOXDTWEUKPND-UHFFFAOYSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
102100030797 Conserved oligomeric Golgi complex subunit 2 Human genes 0.000 description 1
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
241000237858 Gastropoda Species 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
101000920113 Homo sapiens Conserved oligomeric Golgi complex subunit 2 Proteins 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
230000002930 anti-sclerotic effect Effects 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
229940099246 mevacor Drugs 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
230000000051 modifying effect Effects 0.000 description 1
238000007491 morphometric analysis Methods 0.000 description 1
239000000025 natural resin Substances 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
235000021400 peanut butter Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229940089484 pravachol Drugs 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000004218 vascular function Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
229940072168 zocor Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BG102417A 1995-11-02 1998-04-29 Фармацевтичен състав и неговото използване за регулиране на липидната концентрация BG64018B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US615595P	1995-11-02	1995-11-02
PCT/US1996/015854 WO1997016184A1 (en)	1995-11-02	1996-10-02	Method and pharmaceutical composition for regulating lipid concentration

Publications (2)

Publication Number	Publication Date
BG102417A BG102417A (en)	1999-01-29
BG64018B1 true BG64018B1 (bg)	2003-10-31

Family

ID=21719566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102417A BG64018B1 (bg)	1995-11-02	1998-04-29	Фармацевтичен състав и неговото използване за регулиране на липидната концентрация

Country Status (26)

Country	Link
US (3)	US6124309A (pl)
EP (1)	EP0858336B1 (pl)
JP (1)	JPH11515025A (pl)
KR (2)	KR100449604B1 (pl)
CN (2)	CN1217656C (pl)
AR (1)	AR004527A1 (pl)
AT (1)	ATE348607T1 (pl)
AU (1)	AU720853B2 (pl)
BG (1)	BG64018B1 (pl)
BR (1)	BR9611410A (pl)
CZ (1)	CZ127198A3 (pl)
DE (1)	DE69636783T2 (pl)
EA (1)	EA000514B1 (pl)
ES (1)	ES2279526T3 (pl)
GE (1)	GEP20001898B (pl)
HU (1)	HUP9901865A3 (pl)
IL (1)	IL123902A (pl)
IS (1)	IS4720A (pl)
NO (1)	NO981961L (pl)
NZ (2)	NZ512484A (pl)
PL (1)	PL186714B1 (pl)
RO (1)	RO120816B1 (pl)
SK (1)	SK284142B6 (pl)
UA (1)	UA46069C2 (pl)
WO (1)	WO1997016184A1 (pl)
ZA (1)	ZA969187B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6268392B1 (en) *	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
CN1217656C (zh) *	1995-11-02	2005-09-07	沃尼尔·朗伯公司	用于调节脂浓度的方法和药物组合物
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.
EP1514543A1 (en) *	1997-08-29	2005-03-16	Pfizer Inc.	Combination therapy comprising atorvastatin and an antihypertensive agent
GT199800127A (es)	1997-08-29	2000-02-01		Combinaciones terapeuticas.
NZ505994A (en) *	1998-03-17	2003-10-31	Warner Lambert Co	Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
OA11787A (en) *	1998-09-30	2005-07-26	Warner Lambert Co	Method for preventing or delaying catheter-based revascularization.
CO5140104A1 (es) *	1999-02-16	2002-03-22	Novartis Ag	Derivados de mevinolina y preparacion farmaceuticas que los contienen
US20010006656A1 (en) *	1999-02-17	2001-07-05	University Of Washington	Methods and compositions for inhibiting inflammation associated with pulmonary disease
AU7717500A (en) *	1999-09-30	2001-04-30	Merck & Co., Inc.	Anti-hypercholesterolemic drug combination
EP1092432A1 (fr)	1999-10-15	2001-04-18	Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.)	Composes anti-ischemiques
CN1414848A (zh) *	1999-11-05	2003-04-30	沃尼尔·朗伯公司	Acat抑制剂对斑块破裂的预防
HUP0301728A3 (en) *	2000-09-01	2004-05-28	Sankyo Co	Hmg-coa reductase inhibiting pharmaceutical compositions and their use
IL155246A0 (en)	2000-10-11	2003-11-23	Esperion Therapeutics Inc	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) *	2000-10-11	2004-06-24	Esperion Therapeutics, Inc.	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
CA2425311C (en)	2000-10-11	2011-06-14	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
US6713507B2 (en)	2000-10-11	2004-03-30	Esperion Therapeutics, Inc.	Ether compounds and compositions for cholesterol management and related uses
US7304093B2 (en) *	2000-10-11	2007-12-04	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
AU2002211666A1 (en)	2000-10-11	2002-04-22	Esperion Therapeutics, Inc.	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
CA2369967A1 (en) *	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methods of treating nuclear factor-kappa b mediated diseases and disorders
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
US20040204502A1 (en) *	2001-10-11	2004-10-14	Dasseux Jean-Louis Henri	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) *	2001-10-11	2005-01-27	Dasseux Jean-Louis Henri	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) *	2001-10-11	2004-09-30	Dasseux Jean-Louis Henri	Ether compounds and compositions for cholesterol management and related uses
CA2478184A1 (en) *	2002-03-12	2003-09-25	Merck & Co., Inc.	Drug combination therapy
EP1495034A2 (en) *	2002-04-10	2005-01-12	Esperion Therapeutics, Inc.	Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
JP4187141B2 (ja) *	2002-04-12	2008-11-26	興和株式会社	新規なトロンボモジュリン発現促進剤
CA2513660C (en) *	2003-01-23	2012-05-08	Esperion Therapeutics, Inc.	Hydroxyl compounds and compositions for cholesterol management and related uses
NZ544803A (en)	2003-08-29	2009-11-27	Kowa Co	Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
US20090110760A1 (en) *	2003-11-07	2009-04-30	Toyo Shinyaku Co., Ltd.	Lipometabolism improver containing pine bark extract
WO2005068412A1 (en)	2003-12-24	2005-07-28	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
WO2005102348A1 (en) *	2004-04-19	2005-11-03	Loma Linda University	Composition and method of decreasing renal ischemic damage
TW200605890A (en) *	2004-07-28	2006-02-16	Sankyo Co	Pharmaceutical compositions for inhibiting arteriosclerosis
KR101021828B1 (ko) *	2004-10-27	2011-03-17	다이이찌 산쿄 가부시키가이샤	2 이상의 치환기를 갖는 벤젠 화합물
TW200619204A (en) *	2004-12-10	2006-06-16	Kowa Co	Method for reduction, stabilization and prevention of rupture of lipid rich plaque
SG166829A1 (en) *	2005-11-08	2010-12-29	Ranbaxy Lab Ltd	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
RU2308947C1 (ru) *	2006-02-26	2007-10-27	Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН)	Лекарственное средство с гиполипидемическим эффектом "симваглизин"
ES2385752T3 (es)	2006-04-26	2012-07-31	Rosemont Pharmaceuticals Ltd	Composiciones orales líquidas
US20130254787A1 (en)	2006-05-02	2013-09-26	Invidi Technologies Corporation	Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising
US20070269503A1 (en) *	2006-05-16	2007-11-22	James Walter Burgess	Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US8314080B2 (en)	2010-04-06	2012-11-20	Kuwait University	Method of treating type I diabetes
CN102424663B (zh) *	2010-12-03	2013-08-14	天津滨江药物研发有限公司	一种阿托伐他汀氨基酸盐及其制备方法
US8586527B2 (en) *	2011-10-20	2013-11-19	Jaipal Singh	Cerivastatin to treat pulmonary disorders
KR102051031B1 (ko)	2011-10-28	2019-12-02	루메나 파마수티컬즈, 인코포레이티드	고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt)	2011-10-28	2021-02-23	Lumena Pharmaceuticals Llc	uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
CN103304496A (zh) *	2012-03-08	2013-09-18	南京工业大学	一种合成申嗪霉素方法
ES2688879T3 (es)	2012-05-16	2018-11-07	Prairie Berry Europe Gmbh	Ácidos triterpénicos pentacíclicos polihidroxilados como inhibidores de la HMG-CoA reductasa
CN107530307A (zh)	2015-03-13	2018-01-02	艾斯柏伦治疗公司	包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP4438114A3 (en)	2019-06-21	2024-12-25	Esperion Therapeutics, Inc.	Methods of making bempedoic acid and compositions of the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4739073A (en) *	1983-11-04	1988-04-19	Sandoz Pharmaceuticals Corp.	Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2003478A1 (en) *	1988-12-12	1990-06-12	Leonard G. Dennick	Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (en) *	1990-08-23	1992-02-24	Henry Y. Pan	Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
TW223059B (pl)	1991-07-23	1994-05-01	Schering Corp
WO1994009774A1 (en) *	1992-10-26	1994-05-11	Merck & Co., Inc.	Biologically active compounds and process therefor
LT3300B (en)	1992-12-23	1995-06-26	Schering Corp	Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5491172A (en) *	1993-05-14	1996-02-13	Warner-Lambert Company	N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) *	1993-05-14	2001-01-11	Warner Lambert Co	Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
WO1995013063A1 (en) *	1993-11-09	1995-05-18	Merck & Co., Inc.	HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
CN1217656C (zh) *	1995-11-02	2005-09-07	沃尼尔·朗伯公司	用于调节脂浓度的方法和药物组合物

1996
- 1996-10-02 CN CN961980109A patent/CN1217656C/zh not_active Expired - Fee Related
- 1996-10-02 EA EA199800420A patent/EA000514B1/ru not_active IP Right Cessation
- 1996-10-02 DE DE69636783T patent/DE69636783T2/de not_active Expired - Fee Related
- 1996-10-02 US US09/051,368 patent/US6124309A/en not_active Expired - Fee Related
- 1996-10-02 SK SK557-98A patent/SK284142B6/sk unknown
- 1996-10-02 UA UA98052811A patent/UA46069C2/uk unknown
- 1996-10-02 AT AT96934020T patent/ATE348607T1/de not_active IP Right Cessation
- 1996-10-02 GE GEAP19964269A patent/GEP20001898B/en unknown
- 1996-10-02 JP JP9517342A patent/JPH11515025A/ja not_active Ceased
- 1996-10-02 IL IL12390296A patent/IL123902A/xx not_active IP Right Cessation
- 1996-10-02 AU AU72539/96A patent/AU720853B2/en not_active Ceased
- 1996-10-02 PL PL96326365A patent/PL186714B1/pl not_active IP Right Cessation
- 1996-10-02 WO PCT/US1996/015854 patent/WO1997016184A1/en not_active Ceased
- 1996-10-02 CN CNA2005100517235A patent/CN1679953A/zh active Pending
- 1996-10-02 EP EP96934020A patent/EP0858336B1/en not_active Revoked
- 1996-10-02 KR KR10-1998-0703240A patent/KR100449604B1/ko not_active Expired - Fee Related
- 1996-10-02 HU HU9901865A patent/HUP9901865A3/hu unknown
- 1996-10-02 NZ NZ512484A patent/NZ512484A/xx unknown
- 1996-10-02 RO RO98-00919A patent/RO120816B1/ro unknown
- 1996-10-02 CZ CZ981271A patent/CZ127198A3/cs unknown
- 1996-10-02 BR BR9611410A patent/BR9611410A/pt not_active Application Discontinuation
- 1996-10-02 ES ES96934020T patent/ES2279526T3/es not_active Expired - Lifetime
- 1996-10-02 NZ NZ319906A patent/NZ319906A/en unknown
- 1996-10-02 KR KR10-2004-7003107A patent/KR20040029459A/ko not_active Ceased
- 1996-10-31 ZA ZA969187A patent/ZA969187B/xx unknown
- 1996-11-01 AR ARP960105005A patent/AR004527A1/es unknown
1998
- 1998-04-17 IS IS4720A patent/IS4720A/is unknown
- 1998-04-29 BG BG102417A patent/BG64018B1/bg unknown
- 1998-04-30 NO NO981961A patent/NO981961L/no unknown
1999
- 1999-07-01 US US09/346,503 patent/US6143755A/en not_active Expired - Fee Related
- 1999-07-01 US US09/345,944 patent/US6093719A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUP9901865A2 (hu)	1999-10-28
BR9611410A (pt)	1999-01-05
CN1217656C (zh)	2005-09-07
BG102417A (en)	1999-01-29
CZ127198A3 (cs)	1998-12-16
NZ512484A (en)	2003-02-28
AR004527A1 (es)	1998-12-16
ZA969187B (en)	1997-05-29
RO120816B1 (ro)	2006-08-30
UA46069C2 (uk)	2002-05-15
HUP9901865A3 (en)	2000-06-28
PL326365A1 (en)	1998-09-14
PL186714B1 (pl)	2004-02-27
IL123902A (en)	2003-01-12
EP0858336A1 (en)	1998-08-19
CN1201389A (zh)	1998-12-09
US6093719A (en)	2000-07-25
ES2279526T3 (es)	2007-08-16
AU720853B2 (en)	2000-06-15
DE69636783T2 (de)	2007-10-18
ATE348607T1 (de)	2007-01-15
SK284142B6 (sk)	2004-10-05
EA199800420A1 (ru)	1998-10-29
US6124309A (en)	2000-09-26
US6143755A (en)	2000-11-07
JPH11515025A (ja)	1999-12-21
EA000514B1 (ru)	1999-10-28
EP0858336B1 (en)	2006-12-20
AU7253996A (en)	1997-05-22
CN1679953A (zh)	2005-10-12
WO1997016184A1 (en)	1997-05-09
NO981961D0 (no)	1998-04-30
SK55798A3 (en)	1999-06-11
IS4720A (is)	1998-04-17
NZ319906A (en)	2000-02-28
HK1016509A1 (en)	1999-11-05
KR20040029459A (ko)	2004-04-06
NO981961L (no)	1998-05-04
DE69636783D1 (de)	2007-02-01
GEP20001898B (en)	2000-01-05
IL123902A0 (en)	1998-10-30
KR100449604B1 (ko)	2004-11-16
KR19990067270A (ko)	1999-08-16

Publication	Publication Date	Title
AU720853B2 (en)	2000-06-15	Method and pharmaceutical composition for regulating lipid concentration
ES2303603T3 (es)	2008-08-16	Composicion sin acido ascorbico que comprende un inhibidor de la absorcion de colesterol, un inhibidor de la hmg-coa reductasa y un agente estabilizador.
US5190970A (en)	1993-03-02	Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5691375A (en)	1997-11-25	Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
ES2334672T3 (es)	2010-03-15	Composicion farmaceutica que comprende un combinacion de metformina y una estatina.
CA2052014A1 (en)	1992-04-20	Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JPH08291082A (ja)	1996-11-05	二次心臓発作の予防用組成物
JPH04225916A (ja)	1992-08-14	脂血障害の治療用組成物
JPH04243839A (ja)	1992-08-31	ＨＭＧ　ＣｏＡリダクターゼインヒビター含有医薬
KR20080033410A (ko)	2008-04-16	페노피브레이트 및 스타틴을 포함하는 신규한 제제 및 관련치료방법
CA2233558C (en)	2005-12-06	Method and pharmaceutical composition for regulating lipid concentration
WO2012092103A1 (en)	2012-07-05	Gemcabene and derivatives for treating pancreatitis
CA2413906A1 (en)	2001-12-13	Carboxyalkylether-acat inhibitor combinations
HK1078456A (en)	2006-03-17	A pharmaceutical combination for regulating lipid concentration
HK1016509B (en)	2006-03-24	Method and pharmaceutical composition for regulating lipid concentration